The VELO trial reported by Napolitano et al. analyzed plasma ctDNA in patients with CRC having RAS/BRAF-WT before treatment; in their study, the median progression-free survival was 4.5 months in the panitumumab plus trifluridine-tipiracil group (95% confidence interval: 2.2–6.8 months) vs. 2.6 months in the trifluridine–tipiracil only group (95% confidence interval: 1.0–4.3 months) (Napolitano et al. 2023). Here, BRAF is linked to colorectal carcinoma.